Leerink Partners Issues Positive Forecast for Xeris Biopharma (NASDAQ:XERS) Stock Price

Xeris Biopharma (NASDAQ:XERS) had its price target upped by Leerink Partners from $5.00 to $6.00 in a report released on Friday,Benzinga reports. The brokerage currently has an “outperform” rating on the stock. Leerink Partners’ price target would indicate a potential upside of 42.42% from the company’s previous close.

Other analysts also recently issued research reports about the company. Jefferies Financial Group restated a “buy” rating and set a $6.00 price objective (up previously from $4.00) on shares of Xeris Biopharma in a report on Wednesday, January 29th. HC Wainwright reiterated a “buy” rating and issued a $8.00 target price (up previously from $6.60) on shares of Xeris Biopharma in a report on Friday. Craig Hallum increased their price target on shares of Xeris Biopharma from $5.00 to $6.50 and gave the stock a “buy” rating in a research report on Friday. Finally, Piper Sandler reiterated a “neutral” rating and issued a $4.00 price objective (up previously from $3.00) on shares of Xeris Biopharma in a research note on Friday. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $5.92.

Xeris Biopharma Stock Down 0.6 %

NASDAQ XERS traded down $0.03 on Friday, hitting $4.21. The stock had a trading volume of 588,158 shares, compared to its average volume of 1,907,529. The company’s 50-day moving average is $3.57 and its two-hundred day moving average is $3.26. The stock has a market cap of $628.08 million, a price-to-earnings ratio of -9.30 and a beta of 2.32. Xeris Biopharma has a one year low of $1.69 and a one year high of $4.50.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. NewEdge Advisors LLC bought a new stake in Xeris Biopharma during the fourth quarter worth approximately $34,000. Wealth Enhancement Advisory Services LLC bought a new stake in shares of Xeris Biopharma during the 3rd quarter worth $35,000. R Squared Ltd acquired a new position in Xeris Biopharma in the 4th quarter valued at $42,000. Quantbot Technologies LP bought a new position in Xeris Biopharma in the 3rd quarter worth $44,000. Finally, Cibc World Markets Corp acquired a new position in Xeris Biopharma during the 4th quarter worth $44,000. Institutional investors and hedge funds own 42.75% of the company’s stock.

About Xeris Biopharma

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.